Table 2 LMWH in the outpatient treatment of deep venous thrombosis
From: Low-molecular-weight heparins in the treatment of venous thromboembolism
Adverse event | LMWH | Unfractionated heparin | Risk reduction |
|---|---|---|---|
Recurrent venous thromboembolism | 4.45% | 7.02% | 37% |
Major haemorrhage | 1.00% | 2.31% | 57% |
Death | 4.55% | 7.12% | 36% |